BioMarin Pharmaceutical Inc. (LON:0HNC)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 9.97B +21.8% |
| Revenue (ttm) | 2.57B +11.2% |
| Net Income | 55.00M -88.9% |
| EPS | 0.29 -88.9% |
| Shares Out | n/a |
| PE Ratio | 181.20 |
| Forward PE | 10.97 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 404 |
| Open | 69.55 |
| Previous Close | 69.15 |
| Day's Range | 67.61 - 70.24 |
| 52-Week Range | 49.39 - 70.59 |
| Beta | 0.23 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NA... [Read more]
Financial Performance
In 2025, BioMarin Pharmaceutical's revenue was $3.22 billion, an increase of 12.87% compared to the previous year's $2.85 billion. Earnings were $348.90 million, a decrease of -18.26%.
Financial numbers in USD Financial StatementsNews
BioMarin Pharmaceutical Transcript: Canaccord Genuity's 46th Annual Growth Conference
Rare disease focus and global scale drive strong revenue growth and improved profitability. Amicus acquisition accelerates de-leveraging and adds high-growth assets, while VOXZOGO and pipeline expansion support future growth.
BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston
SAN RAFAEL, Calif., Aug. 10, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesda...
BioMarin price target raised to $114 from $111 at Canaccord
Canaccord analyst Whitney Ijem raised the firm’s price target on BioMarin (BMRN) to $114 from $111 and keeps a Buy rating on the shares. The firm updated its model following…
BioMarin price target raised to $80 from $75 at Wells Fargo
Wells Fargo raised the firm’s price target on BioMarin (BMRN) to $80 from $75 and keeps an Overweight rating on the shares. The firm says the company’s Amicus guidance underscores…
BioMarin price target raised to $86 from $80 at BofA
BofA analyst Jason Zemansky raised the firm’s price target on BioMarin (BMRN) to $86 from $80 and keeps a Buy rating on the shares. BioMarin’s Q2 was a beat and…
BioMarin price target raised to $124 from $119 at Morgan Stanley
Morgan Stanley raised the firm’s price target on BioMarin (BMRN) to $124 from $119 and keeps an Overweight rating on the shares.
BioMarin price target raised to $105 from $100 at Raymond James
Raymond James raised the firm’s price target on BioMarin (BMRN) to $105 from $100 and keeps an Outperform rating on the shares.
BioMarin price target raised to $70 from $68 at Stifel
Stifel raised the firm’s price target on BioMarin (BMRN) to $70 from $68 and keeps a Hold rating on the shares.
BioMarin price target raised to $97 from $95 at Oppenheimer
Oppenheimer raised the firm’s price target on BioMarin (BMRN) to $97 from $95 and keeps an Outperform rating on the shares. The firm notes the company reported Q2 revenue of…
BioMarin price target raised to $60 from $50 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on BioMarin (BMRN) to $60 from $50 and keeps a Neutral rating on the shares post the Q2 report. While Voxzogo absorbed the…
BioMarin Pharmaceutical Earnings Call Transcript: Q2 2026
Q2 revenue grew 20% year-over-year to nearly $1 billion, driven by strong commercial execution and the successful Amicus integration. Raised full-year guidance for revenue and EPS, with VOXZOGO, GALAFOLD, and POMBILITI/OPFOLDA all on track for blockbuster status. Integration synergies and pipeline progress support a robust outlook.
BioMarin Pharmaceutical Slides: Q2 2026
BioMarin Pharmaceutical has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
BioMarin Pharmaceutical Earnings release: Q2 2026
BioMarin Pharmaceutical released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
BioMarin Pharmaceutical Quarterly report: Q2 2026
BioMarin Pharmaceutical has published its Q2 2026 quarterly earnings report on August 6, 2026.
BioMarin reports Q2 non-GAAP EPS $1.20, consensus 95c
Reports Q2 revenue $990M, consensus $932.04M. “This quarter, we executed strongly across our portfolio while rapidly integrating Amicus into BioMarin’s (BMRN) operations and advancing plans to acceler...
BioMarin Reports Second Quarter 2026 Financial and Operating Results
Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 million Stronger Growth Expectations Drive Increased Guidance for Full-year 2026 Total Revenues, VOXZOGO®, and Non-GAAP Diluted ...
Spruce Biosciences appoints Jessica Cohen Pfeffer as VP, clinical development
Spruce Biosciences (SPRB) announced the appointment of Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development. Cohen Pfeffer joins Spruce from BioMarin Pharmaceutical (BMRN), where she s...
BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET
SAN RAFAEL, Calif., July 30, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a confe...
BioMarin and n-Lorem Foundation enter research collaboration in ReNU syndrome
BioMarin (BMRN) and n-Lorem Foundation, a nonprofit organization, announced a strategic collaboration and global exclusive license agreement to develop a first-in-disease, antisense oligonucleotide me...
BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome
ReNU syndrome was discovered in 2024 and there are no medicines approved for the condition Collaboration combines BioMarin's leadership in genetic medicines with n-Lorem's pioneering antisense experti...
BioMarin price target raised to $76 from $75 at Citi
Citi analyst Eric Joseph raised the firm’s price target on BioMarin (BMRN) to $76 from $75 and keeps a Buy rating on the shares. The firm adjusted models in the…
BioMarin announces FDA accepts sNDA for full approval of Voxzogo
BioMarin (BMRN) Pharmaceutical announced that the U.S. FDA has accepted the company’s supplemental New Drug Application for Voxzogo for full approval in children with achondroplasia. The FDA has set a...
U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia
Application based on long-term safety and efficacy data from three ongoing studies, including adult height and additional clinical outcomes beyond linear growth, including body proportionality and arm...
BioMarin price target lowered to $62 from $66 at RBC Capital
RBC Capital analyst Luca Issi lowered the firm’s price target on BioMarin (BMRN) to $62 from $66 and keeps a Sector Perform rating on the shares as part of a…
BioMarin’s Voxzogo and BMN 333 show impact in hypochondroplasia, achondroplasia
BioMarin (BMRN) Pharmaceutical announced new data from studies of Voxzogo – vosoritide – in children with hypochondroplasia and the investigational medicine BMN 333 in achondroplasia presented at the ...